MNOV — MEDICINOVA INC
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1226616 ·
Last close
$1.34
Market Cap
$68.65M
52W High
$3.90
52W Low
$1.22
ADV30
61,093
Next earnings
2026-11-12
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 138,555 | 55,849 | -3,060,224 | -2,842,962 | 45,242,293 | 29,256,294 | 4,147,795 |
| Jun 2026 | 458,439 | 317,759 | -2,541,189 | -2,314,139 | 40,433,469 | 25,415,921 | 3,162,867 |
| Mar 2026 | 186,984 | 16,883 | -2,835,806 | -2,586,258 | 42,704,854 | 27,329,415 | 3,297,620 |
| Dec 2025 | 151,739 | 4,754 | -3,092,402 | -2,802,279 | 45,603,109 | 30,806,477 | 4,016,428 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-9,110,256
Investing CF
$-13,724
Financing CF
—
CapEx
$-10,825
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.23
As of
2026-11-15
Balance + Analyst (yfinance extras)
Retained Earnings
$-443,649,596
Inventory
—
Receivables
$245,100
ST Investments
—
EBIT TTM
$-11,850,395
Pretax Income TTM
$-10,747,055
Interest Exp TTM
—
Analysts
4
Yahoo Snapshot (yfinance, live)
Total Revenue
$935,717
EBITDA
$-11,512,367
Free Cash Flow
$-6,790,181
Enterprise Value
$42,313,812
Total Cash
$29,256,294
Total Debt
$100,536
Shares Out
51,232,668
Trailing EPS
$-0.21
Book Value
$0.76
ROE
-24.8%
ROA
-15.5%
Div Yield
0.00%
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 409,657 | -13,283,002 | -11,997,957 | 45,603,109 | 4,016,428 | 41,586,681 | -9,810,061 |
| Dec 2024 | 0 | -12,675,331 | -11,049,549 | 55,875,926 | 3,372,375 | 52,503,551 | -10,642,964 |
| Dec 2023 | 1,000,000 | -9,900,265 | -8,571,516 | 66,269,977 | 3,891,553 | 62,378,424 | -7,431,038 |
| Dec 2022 | 0 | -14,628,649 | -14,069,083 | 74,154,905 | 3,912,870 | 70,242,035 | -12,911,563 |
TTM Snapshot
Revenues TTM
$920,481
NetIncome TTM
$-10,753,049
OpCashFlow TTM
—
Assets (Latest)
$40,433,469
Forward EPS
$-0.52
Max Pain — expiry 2027-01-15 (volume-derived — Yahoo OI feed degraded)
max pain strike: $2.50 · spot: $1.33 · call volume: 1 · put volume: 1
Expected Move to 2027-01-15:
±$1.38
(103.38%) —
implied range
$-0.04 –
$2.71
· ATM straddle on $2.50 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| CING | Cingulate Inc. | $68.64M | $4.72 | — |
| VTVT | vTv Therapeutics Inc. | $69.36M | $17.29 | — |
| GOSS | Gossamer Bio, Inc. | $67.52M | $11.04 | — |
| COYA | Coya Therapeutics, Inc. | $70.84M | $3.02 | — |
| KALA | KALA BIO, Inc. | $66.34M | $3.43 | — |
News headlines (Yahoo Finance, 1h cache)
MediciNova (MNOV) Reports Q3 Loss, Misses Revenue Estimates
2026-11-12 23:35 · Yahoo
MediciNova: Q3 Earnings Snapshot
2026-11-12 22:32 · Yahoo
MediciNova CEO Provides Shareholder Update
2026-10-12 10:00 · Yahoo
MediciNova to Participate in the Maxim Growth Summit
2026-10-06 10:00 · Yahoo
MediciNova Drug Falls Short on Liver Fat Parameter, Stock Tumbles
2026-09-28 15:10 · Yahoo
MediciNova Shares Fall After Phase 2 Tipelukast Trial Misses Primary Endpoints
2026-09-28 13:58 · Yahoo
MediciNova stock tumbles on mixed Phase 2 NAFLD trial data
2026-09-28 13:20 · Yahoo
MediciNova Announces Topline Results from MN-001-NATG-202 Clinical Trial of MN-001 (Tipelukast)
2026-09-28 10:00 · Yahoo
MediciNova Announces Completion of Last Patient, Last Visit in the Double-Blind Portion of the Phase 2b/3 COMBAT-ALS Trial of MN-166 (Ibudilast)
2026-09-24 10:00 · Yahoo
MediciNova to Participate in Two Investor Conferences in September
2026-09-08 10:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.